Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort
Background: Claudin 18.2 (CLDN18.2) is highly expressed in up to 40% of gastroesophageal adenocarcinomas (GEA) and represents an emerging therapeutic target for these tumors. However, its distribution across molecular subtypes and its prognostic and predictive roles remain insufficiently studied. Me...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p6982 |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/6982 |
| Access Level: | acceso abierto |
| Palabra clave: | gastroesophageal adenocarcinoma Claudin 18.2 HER2 PD-L1 overlapping biomarkers targeted therapies immunotherapy |
| Sumario: | Background: Claudin 18.2 (CLDN18.2) is highly expressed in up to 40% of gastroesophageal adenocarcinomas (GEA) and represents an emerging therapeutic target for these tumors. However, its distribution across molecular subtypes and its prognostic and predictive roles remain insufficiently studied. Methods: This ambispective, multicenter study included 563 patients with GEA diagnosed between 2019 and 2025 across 17 European institutions.Tumor samples were analyzed for CLDN18.2, human epidermal growth factor receptor 2 (HER2), mismatch repair, Epstein-Barr virus (EBV), and programmed death-ligand 1 [PD-L1; combined positive score (CPS)] using immunohistochemistry and/or in situ hybridization. Molecular alterations were characterized using next-generation sequencing. Associations between molecular features and clinical outcomes, such as overall response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS), were evaluated. Results: High CLDN18.2 expression was observed in 48.3% of tumors, correlating with diffuse-type histology and peritoneal involvement (P < 0.01). Its prevalence varied across molecular subtypes: 33.9% in deficient mismatch repair, 62.5% in EBV-positive, 41.9% in HER2-positive tumors, and 47.2% in tumors with PD-L1 CPS >= 5. Among patients treated with first-line chemotherapy, CLDN18.2 status did not affect mPFS [hazard ratio (HR) 0.90; P = 0.50] or mOS (HR 1.06; P = 0.80). However, among HER2-positive patients, CLDN18.2-high tumors were associated with improved outcomes with HER2-targeted therapy (mPFS 17.0 versus 8.9 months, HR 0.42; P = 0.03; mOS 43.0 versus 23.0 months, HR 0.40; P = 0.07). By contrast, in patients with CLDN18.2-high tumors receiving an immunotherapy-based regimen (IO), there was a trend toward lower ORR (51% versus 64%; P = 0.15), shorter mPFS (8.9 versus 14.0 months; HR 1.47; P = 0.14), and reduced mOS (16.0 versus 43.0 months; HR 2.04; P = 0.052). Combined analyses of CLDN18.2 and PD-L1 showed poorer survival outcomes in CLDN18.2-high tumors across PD-L1 thresholds. Conclusions: CLDN18.2-high GEA was more prevalent than previously reported in pivotal trials and showed substantial overlap across molecular subtypes. It was associated with a greater benefit from HER2-targeted therapy but a trend toward poorer outcomes with IO, underscoring the need for biomarker-guided therapeutic strategies in GEA. |
|---|